Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer

Breast Cancer Research and Treatment

Volumn 79, Issue 3, 2003, Pages 301-312

  Tantivejkul, Kwanchanit ^a   Vucenik, Ivana ^a   Eiseman, Julie ^b   Shamsuddin, AbulKalam M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Combination therapy; Phytate; Phytic acid; Synergism

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PHYTIC ACID; TAMOXIFEN; VINBLASTINE; VINCA ALKALOID;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARDIOTOXICITY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0038575866     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024078415339     Document Type: Article

References (48)

1. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham D, Bryant J, Dimitrov N, Abramson N, Atkins J, Shibata H, Deschenes L, Margolese R: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89: 1673-1682, 1997
2. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: Adjuvant systemic therapy for women with node-positive breast cancer. The steering committee on clinical practice guidelines for the care and treatment of breast cancer. CMAJ 158S3: S52-S64, 1998
3. Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A: Chemotherapy v. chemoimmunotherapy (CAF v CAFVP v CMF, each + MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol 5: 1523-1533, 1987
4. Bonadonna G: Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7: 1380-1397, 1989
5. Buzdar A: The place of chemotherapy in the treatment of early breast cancer. Br J Cancer 78: 16-20, 1998
6. Endicott J, Ling V: The biochemistry of p-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989
7. 31P NMR. Biochem Biophys Res Comm 264: 874-881, 1987
8. Sakamoto K, Venkatraman G, Shamsuddin A: Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). Carcinogenesis 14: 1815-1819, 1993
9. Ullah A, Shamsuddin A: Dose-dependent inhibition of large intestinal cancer by inositol hexaphosphate in F344 rats. Carcinogenesis 11: 2219-2222, 1990
10. Vucenik I, Sakamoto K, Bansal M, Shamsuddin A: Inhibition of rat mammary carcinogenesis by inositol hexaphosphate (phytic acid). Cancer Lett 75: 95-101, 1993
11. Vucenik I, Yang G, Shamsuddin A: Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. Carcinogenesis 16: 1055-1058, 1995
12. Vucenik I, Kalebic T, Tantivejkul K, Shamsuddin A: Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo. Anticancer Res 18: 1377-1384, 1998
13. 6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. Anticancer Res 18: 4083-4090, 1998
14. 6) in breast cancer cells is mediated by increase in p27 and decrease in Rb protein phosphorylation. Proc Am Assoc Cancer Res 41: 338 (#2141), 2000
15. Shamsuddin A, Yang G: Inositol hexaphosphate inhibits growth and induces differentiation of PC3 human prostate cancer cells. Carcinogenesis 16: 1975-1979, 1995
16. 6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. Anticancer Res 16: 3287-3292, 1996
17. Shamsuddin A, El-Sayed A, Ullah A: Suppression of large intestinal cancer in F344 rats by inositol hexaphosphate. Carcinogenesis 9: 577-580, 1988
18. Shivapurkar N, Tang Z, Frost A, Alasbaster O: A rapid dual organ rat carcinogenesis bioassay for evaluating the chemoprevention of breast and colon cancer. Cancer Lett 100: 169-179, 1996
19. Batist G, Tulpule A, Sinha B, Katki A, Myers C, Cowan K: Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986
20. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotxicity assays. J Immunol Meth 65: 55-63, 1983
21. Weisenthal L, Dill P, Kurnick N, Lippman M: Comparison of dye exclusion assays with clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res 43: 258-264, 1983
22. Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1987
23. Webb J: Effect of more than one inhibitor. Enzyme and Metabolic Inhibitors. Vol. 1, Academic Press, New York, pp. 488-512, 1963
24. Sartorelli A: Approaches to the combination chemotherapy of transplantable neoplasms. Prog Exp Tumor Res 6: 228-288, 1965
25. Welander C, Morgan T, Homesley H, Trotta P, Spiegel R: Combined recombinant human interferon alpha2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 35: 721-729, 1985
26. Kaufman M, Klinga K, Runnebaum B, Kubli F: In vitro adriamycin sensitivity test and hormonal receptors of primary breast cancer. Cancer 46: 2797-2800, 1980
27. Jones A: Primary medical therapy. Cancer Treatment Rev 23: S33-S39, 1997
28. Wang F, Jiang X, Yang D, Elliott R, Head J: Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res 20: 799-808, 2000
29. Pratt W, Ruddon R, Ensminger W, Maybaum J: The Anticancer Drugs. 2nd edn, Oxford University Press, New York, p. 352, 1994
30. Graf E, Eaton J: Anti-oxidant functions of phytic acid. Free Radical Biol Med 8: 61-69, 1990
31. Chabner B, Allegra C, Curr G, Calabresi P: Antineoplastic agents. In: Molinoff P, Ruddon R (eds) Goodman & Gilman's: the Pharmacological Basis of Therapeutics. 9th edn, McGraw-Hill, New York, pp. 1233-1287, 1996
32. Myers C: Role of iron in anthracycline action. In: Hanker M, Lazo J, Tritton T (eds) Organ-Directed Toxicities of Anticancer Drugs. Marinus Nijhoff, Boston, MA, pp. 17-30, 1988
33. Rao P, Liu X, Das D, Weinstein G, Tyras D: Protection of ischemic heart from reperfusion injury by myo-inositol hexaphosphate, a natural anti-oxidant. Ann Thorac Surg 52: 908-912, 1991
34. Kamp D, Greenberger M, Sbalchierro J, Preusen S, Weitzman S: Cigarette smoke augments asbestos-induced alveolar epithelial cell injury: role of free radicals. Free Radic Biol Med 25: 728-739, 1998
35. Hawkins P, Poyner D, Jackson T, Letcher A, Lander D, Irvine R: Inhibition of iron-catalysed hydroxyl radical formation by inositol polyphosphates: a possible physiological function for myo-inositol hexakisphosphate. Biochem J 294: 929-934, 1993
36. 6 and inositol: adjuvant to chemotherapy of colon cancer. A pilot clinical trial. Rev Oncol 4 (Suppl 1): 171 (#480), 2002
37. Baum M: Polychemotherapy for early breast cancer. Lancet 352: 1554, 1998
38. 6). Anticancer Res 21: 2393-2404, 2001
39. Fisher B, Costantino J, Wickerham D, Redmond C, Kavanah M, Cronin W, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998
40. 6). Anticancer Res 19: 3689-3693, 1999
41. Soule H, Vazquez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973
42. Cailleau R, Young R, Olive M, WJ Reeves J: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53: 661-674, 1974
43. 2+ channel activity by inositol hexaphosphate. Science 278: 471-474, 1997
44. Huang C, Ma W-Y, Hecht S, Dong Z: Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3′ kinase. Cancer Res 57: 2873-2878, 1997
45. 6) differentially modulates the expression of PKCδ in MCF-7 and MDA-MB 231 cells. Proc Am Assoc Cancer Res 40: 653 (#4306), 1999
46. 6 in HT-29 human colon carcinoma cell line. Anticancer Res 18: 1479-1484, 1998
47. York J, Odom A, Murphy R, Ives E, Wente S: A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 285: 96-100, 1999
48. Odom A, Stahlberg A, Wente S, York J: A role for nuclear inositol 1,4,5-triphosphate kinase in transcriptional control. Science 287: 2026-2029, 2000